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Summary
Cetuximab is a monoclonal antibody that treats malignant disease by inhibiting epidermal growth factor receptor. Many common adverse
events have been reported and include skin rashes, infusion reactions, gastrointestinal complaints and headache. Up to now, cetuximab-
associated pulmonary toxicity has been rarely reported in the literature. The present report describes two cases with probable interstitial
pneumonitis 5–6 weeks after commencing treatment with chemotherapy combined with cetuximab. One patient recovered and the
second patient died due to gastrointestinal bleeding 3 weeks after an initial response to steroids.
BACKGROUND
Cetuximab (marketed under the registered trade name
Erbitux) is a chimeric (mouse/human) monoclonal anti-
body which inhibits the epidermal growth factor receptor
(EGFR). Through binding to the extracellular domain of
EGFR, it interrupts the signalling cascade resulting in
inhibition of cell growth and induction of apoptosis.
Furthermore, cetuximab decreases matrix metalloprotei-
nase and vascular endothelial growth factor production.1
It is administered by intravenous infusion for treatment
of EGFR expressing metastatic colorectal cancer and squa-
mous cell carcinoma of the head and neck.2 Cetuximab-
associated pulmonary toxicity has been rarely described in
the literature.3 4 Here, we report on two patients who
acquired an interstitial pneumonia most likely caused by
cetuximab, since these patients did not improve despite
the initiation of antimicrobial treatment.
CASE PRESENTATION
Case 1
A 61-year-old Caucasian man was admitted to our hos-
pital with dyphagia resulting in a weight loss of 5 kg
undergoing treatment for a cT4b cN2c mesopharynx car-
cinoma diagnosed 2 months ago. Induction chemotherapy
with three cycles of docetaxel, cisplatin and 5-ﬂuorouracil
was administered. As a complication of this treatment,
the patient developed febrile neutropenia without a septic
focus and was empirically treated with cefepime. After
partial remission, intensity-modulated radiation therapy
was administered to the primary tumour including lymph
nodes to a total dose of 70 Gy given in daily 2-Gy frac-
tions combined with cetuximab (total six cycles, loading
dose 600 mg, then 400 mg). On admission, the patient
had no fever and physical examination revealed an acne-
like skin rash of the neck which is a common side effect
of cetuximab. Laboratory tests showed an elevated
C-reactive protein of 106 mg/l. White blood cell count
was normal with 3560/μl. No chest x-ray was performed
in the absence of pulmonary symptoms. Gastroscopy
showed an erosive bulbitis which was interpreted along
with the mucositis within the radiation ﬁeld, as an add-
itional cause of the dysphagia. The patient was com-
menced on amoxicillin/clavulanic acid on the assumption
of a superinfection within the mesopharynx and on a
proton pump inhibitor to treat the erosive bulbitis. In
addition, a percutaneous endoscopic gastrostomy (PEG)
was placed. A few days later, the patient developed pain
in the upper abdomen and the PEG insertion site was
slightly erythematous, suggestive of a PEG site infection.
A superﬁcial swab revealed growth of Enterobacter cloacae
(with AmpC expression). Therefore, antimicrobial treat-
ment was switched to ertapenem. Owing to increased
infective parameter (C-reactive protein of 165 mg/l), the
infectious diseases service was consulted regarding further
diagnostic steps and treatment.
Patient 2
The second patient, a 65-year-old Caucasian man, was
also admitted to our hospital for commencement of PEG
or nasogastric feeding for management of dyphagia. He
suffered from both tonsillar squamous cell carcinoma and
oesophageal adenocarcinoma. For the former, radiotherapy
was administered starting 4 weeks before admission in
combination with cetuximab 2 weeks after starting radio-
therapy. Carboplatin and taxol were added for treatment
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of the oesopophageal carcinoma. Four days after stopping
cetuximab and carboplatin, the patient developed fever
with left renal pain. Physical examination revealed no
pathological ﬁndings except for dermatitis of the neck
which was interpreted as cetuximab-associated skin tox-
icity. Empiric antibiotic treatment with ceftriaxone was
started, assuming a nosocomial pyelonephritis. The infec-
tious diseases service was consulted for advice regarding
further management.
INVESTIGATIONS AND TREATMENT
Patient 1
Owing to persistent subfebrile temperatures and previous
abdominal pain, nosocomial urinary tract infection or
catheter-related blood stream infections were excluded by
repeated blood and urine cultures. No ascites or signs of
cholecystitis were observed in ultrasound and CT of the
abdomen. A subsequent CT of the lung showed ground-
glass consolidation in the upper lobe and a small area of
consolidation in the inferior lobe of the right lung. Owing
to immunosuppression, Pneumocystis jiroveci and Legionella
pneumophila serovar type 1 was excluded by induced
sputum (Immunoﬂuorescence stain, Kinyoun stain) and
by urinary antigen, respectively. A repeat CT due to per-
sistent fever and development of oxygen desaturation
3 days later showed a massive pleura effusion and a large
consolidation with air bronchograms in the upper and
lower lobe of the right lung (ﬁgure 1A). The pleural effu-
sion was punctured and antibiotic treatment was changed
from ertapenem to meropenem. The pleural ﬂuid showed
only 610 cells with 55% neutrophils, 7.5% lymphocytes
and 22% of monocytes. Microbiology testing was nega-
tive. Owing to a high risk of a need for intubation, no
bronchoalveolar lavage (BAL) was performed. The clinical
constellation of persisting fever in the absence of proven
microbial infection, concomitant treatment with a broad
spectrum antibiotic and a ground-glass pattern in the CT
was not suggestive for bacterial pneumonia; therefore,
treatment with oral prednisone 100 mg daily was started.
Patient 2
Pyelonephritis was excluded by ultrasound of the kidney
and by repeated blood and urine cultures. Ceftriaxone was
changed to piperacillin-tazobactam due to the nosocomial
setting. Four days later, the patient developed a productive
cough with yellow sputum and dyspnoea. Chest x-ray
showed an inﬁltrate below the right hilum. CT excluded
pulmonary emboli and revealed large ground-glass opaci-
ties in both lungs (ﬁgure 2). Owing to increased dyspnoea
5 days after the onset of fever, a BAL was performed
and intravenous trimethoprim/sulfamethoxazole (320/
1600 mg) four times a day and oral prednisone (40 mg)
twice a day was empirically started due to possible P jiro-
veci pneumonia. BAL showed a total cell count of 100/µl
(23% neutrophil granulocytes, 6.5% lymphocytes and
70.5% macrophages) without growth of bacteria, myco-
bacteria or fungi and immunoﬂuorescent stainings for
P jiroveci were negative. Molecular analyses of respiratory
viruses including adenovirus, rhinovirus, cytomegalovirus,
human respiratory syncytial virus, inﬂuenza and para-
inﬂuenza, were negative. No peripheral eosinophilia was
documented.
DIFFERENTIAL DIAGNOSIS
Patient 1
Differential diagnosis included bacterial, viral or fungal
pneumonia, or toxic pneumonitis due to cetuximab. The
lung pathology as demonstrated on CTwas clearly outside
Figure 1 Radiological ﬁnding in patient number 1. (A) Two CT
scans of the lung 3 days apart showing a rapid progressive
inﬁltrate prior to steroid treatment (attached as TIFF graphic).
(B) Conventional chest x-ray 7 days after steroid treatment.
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of the radiation ﬁelds; thus, irradiation pneumonitis could
be excluded.
Patient 2
Owing to administration of cetuximab and taxotere, a
toxic pneumonitis was proposed. Differential diagnoses of
the pulmonary damage were previous radiotherapy,
lymphangitis carcinomatosis or pneumonia due to virus,
atypical bacteria or fungi which was unable to be isolated
in the BAL.
OUTCOME AND FOLLOW-UP
Patient 1
Fever normalised within 2 days of steroid treatment.
C-reactive protein decreased from a maximum value of
126 to 8.6 mg/l in 7 days and chest x-ray was almost
normal at that time (see ﬁgure 1B). The patient was dis-
charged 10 days after starting steroids.
Patient 2
Within 5 days after starting steroids, symptoms and
laboratory ﬁndings markedly improved. However, 15 days
later, the patient required admission to the intensive care
unit due to gastrointestinal bleeding. He developed a
severe acute respiratory distress syndrome (ARDS), includ-
ing a multiple organ dysfunction syndrome and died
5 days later. Autopsy showed bronchitis with diffuse
alveolar dysfunction with several small lung metastases of
2 mm (squamous cell carcinoma). Additionally, a throm-
botic endocarditis of the mitral valve with ischaemic
infarction of the heart, brain, kidney and spleen was
reported.
DISCUSSION
Five to 6 weeks after starting treatment with cetuximab
both patients presented with fever, shortness of breath
and pulmonary ground-glass opacities and consolidation
in CT. Interstitial pneumonia was suspected. Whereas in
patient 1 the CT-ﬁndings were comparable to a crypto-
genic organising pneumonia caused by drugs, the ground-
glass opacities in patient 2 were similar to an exogenic
allergic alveolitis. Whereas no causative pathogen of the
pneumonia was found (negative pleura effusion in patient 1,
negative bronchoalveolar lavage in patient 2) and no
response to antimicrobial treatment was observed (table 1),
toxic pneumonitis due to previous chemotherapy with
cetuximab, cisplatin/carboplatin, taxol and/or docetaxel
was discussed.
We favoured cetuximab because both patients suffered
from active dermatitis coincidentally and developed pul-
monary signs and symptoms that started 5–6 weeks after
the ﬁrst dose of cetuximab.
In addition to cessation of cetuximab, further strategies
to treat toxic interstitial pneumonitis include symptomatic
treatment and the use of corticosteroids.4 In both patients,
fever, pulmonary signs and C-reactive protein rapidly
resolved within a few days after initiation of steroid treat-
ment. Despite an initial improvement of pneumonitis,
patient 2 developed gastrointestinal bleeding with subse-
quent ARDS resulting in death 5 days later. Alveolar
damage seen at autopsy could not distinguish between
damage due to ARDS after gastrointestinal bleeding, cetux-
imab side effects or other reasons as the pathological ﬁnd-
ings were non-speciﬁc. Nevertheless, the alveolar damage
seemed to be older than 5 days, suggesting cetuximab tox-
icity. Although not proven due to the non-speciﬁc signs
and symptoms, we strongly believe that the interstitial
pneumonia was related to cetuximab therapy.
Cetuximab is a biological treatment of malignancy
which inhibits epidermal growth factor receptor (EGFR).
Common adverse events are dermatologic reactions, infu-
sion reactions, gastrointestinal complaints and headache.5
Up to now, cetuximab-associated pulmonary toxicity has
only rarely been described in the medical literature3 4 6
but there are several reports of interstitial ﬁbrosis in
patients treated with other EGFR inhibitors such as geﬁti-
nib and erlotinib outside of clinical trials. In a retrospect-
ive study of Hoag et al,4 patients with colorectal, lung and
head and neck cancer receiving chemotherapy combined
with cetuximab had signiﬁcantly more pulmonary symp-
toms than patients not receiving cetuximab (10.3% vs
8.3%). In the subanalysis in patients with head and neck
cancer, no signiﬁcant difference was observed (17.9% vs
20.1%). Interestingly, pulmonary side effects in patients
with a non-small cell lung cancer were much more
common in the cetuximab versus the control group
(18.7% vs 12.2%, p<0.001). This may suggest that an
underlying lung disease could be a risk factor for pulmon-
ary cetuximab toxicity. Although our patients lacked an
underlying lung disease they both received previous radio-
chemotherapy. However, up to now there have been no
published reports to support a potential hypothesis that
radiotherapy may be an additional risk factor.
Furthermore, our patients received irradiation outside of
the areas where the interstitial pneumonitis was seen in
CT. In a recently published study from Kang et al6 low
albumin level was identiﬁed as a risk factor for developing
an adverse pulmonary reaction in patient taking cetuxi-
mab, rituximab, trastuzumab or bevacizumab. The low
albumin level in our two patients (28 and 24 g/l) supports
this hypothesis. Both patients were of Caucasian ethni-
city and therefore a genetic causality for the side effects
observed cannot be ruled out. For example, it has been
shown that Stevens-Johnson syndrome and its related
toxic epidermal necrolysis induced by carbamazepine are
strongly linked to the HLA-B 1502 allele7 and severe
Figure 2 Radiological ﬁndings in patient number 2. CT scan of
the lungs prior to steroid treatment demonstrates large bilateral
ground-glass opacities.
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hypersensitivity reactions caused by abacavir were linked
to the HLA-B 5701 allele”.8
In summary, we recommend that clinicians should be
alert to the possibility of adverse pulmonary reactions if
cetuximab treatment has been given in the weeks preced-
ing the onset of pulmonary symptoms. After exclusion of
infectious pneumonia, drug-induced toxicity should be
considered and treatment with corticosteroids should be
promptly started.
Learning points
▸ Clinicians should be aware that in patients treated with
cetuximab interstitial pneumonia can occur as an
adverse reaction of this drug.
▸ After exclusion of infectious pneumonia, treatment with
corticosteroids should be strongly considered for
treatment of cetuximab-associated pneumonia. Rapid
improvement of symptoms and signs upon steroid
treatment is highly suggestive of drug-associated
pulmonary toxicity.
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Table 1 Characteristics of our two patients compared to the only patient reported in the literature so far
Case 1 Case 2 Case 3 (Chua et al3)
Age (year) 61 55 78
Neoplasia Mesopharynx squamous cell carcinoma Tonsillar squamous cell and oesophageal
adeno carcinoma
Metastatic colorectal cancer
Radiotherapy Yes Yes No
Chemotherapy – Docetaxel, cisplatin, 5-FU
– Cetuximab/radiotherapy
– Cetuximab/radiotherapy
– Taxol/carboplatin
– Bevacizumab, 5-FU,
oxaliplatin
– 5-FU, irinotecan
– Cetuximab, irinotecan
Smoker Stopped 1 year ago Stopped 5 months before death Stopped 60 years ago
Previous lung history No No Minor pulmonary fibrosis
Onset of pulmonary
symptoms
– 16 days after last cetuximab dose (400 mg)
– 5 weeks after starting cetuximab
– 8 days after last cetuximab dose
(450 mg)
– 6 weeks after starting cetuximab
– Last dose unknown
– 2 months after starting
cetuximab
Signs and symptoms First fever, followed by dry cough and shortness of
breath
First fever, followed by cough and
shortness of breath
Cough, shortness of breath
CT scan Ground-glass changes and consolidation predominant in
upper and inferior lobe of right lung
Bilateral extensive ground-glass changes Bilateral patchy ground-glass
changes
Bronchoscopy Not performed – 100 cells/µl (23% neutrophile
granulocytes)
– Negative for bacteria, fungi,
pneumocystis jiroveci, mycobacteria and
multiple respiratory viruses
No microorganism was found
(microscopy and culture)
Antibiotic treatment – Amoxicillin-clavulanate 6 days
– Ertapenem 7 days
– Meropenem 14 days
– Ceftriaxone 2 days
– Piperacillin-tazobactam 5 days
– Cotrimoxazole 13 days
– Cefotaxime and azithromycin
for 6 days
Corticosteroids 100 mg prednisone daily for 7 days→ improvement
within 3 days
80 mg prednisone daily for 14 days→
improvement within 6 days
50 mg prednisone daily (unknown
interval→ improvement
Control CT scan or
radiography
No CT scan after clinical improvement. Recovery on
chest x-ray after 10 days
No CT scan because of death CT scan 3 weeks after hospital
admission: improvement
Outcome Alive Death 3 weeks later after gastrointestinal
bleeding (ARDS, MODS)
Death 4 months later due to
pulmonary metastases
Autopsy Not done Diffuse alveolar damage, bronchitis Not done
ARDS, acute respiratory distress syndrome; FU, fluorouracil; MODS, multiple organ dysfunction syndrome.
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